Metastatic Type 1 low-grade gastric neuroendocrine tumor treated with peptide receptor radionuclide therapy in a young adult:a case report  

作　　者：Elisabetta Dell’Unto Maria Rinzivillo Gianluca Esposito Elsa Iannicelli Daniela Prosperi Francesco Panzuto Bruno Annibale 

机构地区：[1]Department of Medical-Surgical Sciences and Translational Medicine,Sapienza University of Rome,Rome,Italy [2]Digestive Disease Unit-ENETS Center of Excellence,Sant’Andrea University Hospital,Italy [3]Radiology Unit-ENETS Center of Excellence,Sant'Andrea University Hospital,Rome,Italy [4]Nuclear Medicine Unit-ENETS Center of Excellence,Sant’Andrea University Hospital,Rome,Italy

出　　处：《Gastroenterology Report》2024年第1期805-807,共3页胃肠病学报道(英文)

基　　金：supported by Sapienza University of Rome[Grant Ateneo 2022 RM12218161A53B1D].

摘　　要：Background Gastric neuroendocrine tumors(g-NETs)are classified into:Type 1,associated with chronic atrophic gastritis(CAG);Type 2,related to Zollinger-Ellison Syndrome/Multiple Endocrine Neoplasia Type 1;and sporadic Type 3[1].Type 1,the most common,typically presents as small,well-differentiated tumors with excellent survival[1].Tumor size and gender are important prognostic factors in Type 1 g-NETs,with a controversial prognostic role of the Ki-67 index[2,3].Metastatic Type 1 g-NETs are rare and treatment of advanced cases mirrors that of other advanced NETs,including somatostatin analogs(SSA)and peptide receptor radionuclide therapy(PRRT),though specific data are limited[1].

关 键 词：ELLISON NEUROENDOCRINE GASTRIC 

分 类 号：R735[医药卫生—肿瘤]